Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold
Published . Updated .
Fintel reports that on October 1, 2026, Argus Research upgraded their outlook for Regeneron Pharmaceuticals (NASDAQGS:REGN) (BIT:1REGN) from Hold to Buy.Regeneron Pharmaceuticals, Inc. is an American biotechnology company primarily engaged in the research, development, and commer
Directly affected
- REGN Regeneron Pharmaceuticals
Named in this report.
Indirectly affected
- NDAA NED DAVIS RESEARCH 360 DYNAMIC ALLOCATION ETF
GA selected NDAA as a RELATED security because its canonical security name directly matches this event's themes: research. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- TSPA T. Rowe Price US Equity Research ETF
GA selected TSPA as a RELATED security because its canonical security name directly matches this event's themes: research. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- XPH STATE STREET SPDR S&P PHARMACEUTICALS ETF
GA selected XPH as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on October 1, 2026, Argus Research upgraded their outlook for Regeneron Pharmaceuticals (NASDAQGS:REGN) (BIT:1REGN) from Hold to Buy.Regeneron Pharmaceuticals, Inc. is an American biotechnology company primarily engaged…
Source: Nasdaq Markets
The price since 1 Oct 2026: Regeneron Pharmaceuticals (REGN) versus the S&P 500
Since the first closing price after “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold,” Regeneron Pharmaceuticals (REGN) is +6.26%. The S&P 500 fund (SPY) is -0.40% over the same days, a +6.65% difference versus the market.
Disclosure records for Regeneron Pharmaceuticals (REGN) within two months of 1 Oct 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Regeneron Pharmaceuticals (REGN)
Companies carried with this story
- REGN Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (REGN) is linked, with no stored direction, high confidence in the 1 Oct 2026 story “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold.” Reason on file: The reported development directly names REGENERON PHARMACEUTICALS in the headline; GA resolved that company to REGN
- NDAA Ned Davis Research 360 Dynamic Allocation Etf
For “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold,” Ned Davis Research 360 Dynamic Allocation Etf (NDAA) is linked, with no stored direction, medium confidence. Reason on file: GA selected NDAA as a RELATED security because its canonical security name directly matches this event's themes: research. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- TSPA T. Rowe Price US Equity Research ETF
For “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold,” T. Rowe Price US Equity Research ETF (TSPA) is linked, with no stored direction, medium confidence. Reason on file: GA selected TSPA as a RELATED security because its canonical security name directly matches this event's themes: research. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- XPH State Street Spdr S&P Pharmaceuticals Etf
In “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold,” State Street Spdr S&P Pharmaceuticals Etf (XPH) is linked, with no stored direction, medium confidence. Reason on file: GA selected XPH as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Regeneron Pharmaceuticals (REGN)
On 1 Oct 2026, “Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold” is the story that connects Regeneron Pharmaceuticals (REGN) to this story.
The link for Regeneron Pharmaceuticals (REGN) is this: The reported development directly names REGENERON PHARMACEUTICALS in the headline; GA resolved that company to REGN
Also listed, Ned Davis Research 360 Dynamic Allocation Etf (NDAA): GA selected NDAA as a RELATED security because its canonical security name directly matches this event's themes: research. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Regeneron Pharmaceuticals (REGN)
NDAA traded between 23.81 and 24.14 across 11 sessions. The latest close on file is 23.88. REGN traded between 722.24 and 808.38 across 13 sessions. The latest close on file is 781.40. TSPA traded between 47.99 and 49.52 across 20 sessions. The latest close on file is 48.33.
How strong the case is around Regeneron Pharmaceuticals (REGN)
33 out of 100
“Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold” scores 33 out of 100. The score uses 1 sources, and 4 linked companies.